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Abstract
Rationale: In psychiatric disorders, interindividual differences in cytochrome P450 (CYP)2D6 (CYP2D6) enzymatic activity could be
responsible of adverse drug reactions (ADRs) and therapeutic failures (TFs) for CYP2D6-metabolized drugs, contributing to the
periodical hospital readmissions of the revolving door (RD) condition.
Patient concerns:We investigatedCYP2D6 genotypes in a controlled series of 5 consecutive RD patients with Bipolar Disorder (BD).
Diagnoses: Psychiatric patients affected by Bipolar Disorder.
Interventions:We defined TFs as a difference at the Brief Psychiatric Rating Scale score DBPRS<25% at each 1-week of stable
treatment, and ADRs as the onset of extrapyramidal symptoms and/or metabolic impairment with weight gain.
Outcomes: At 3 months, a mean number of 2.75±1.26 ADR and a mean DBPRS score of 16.07±0.05% were observed. At 6
months of follow-up, compared to the only patient without BD (DBPRS<32.10%), BD patients (n=4) showed TFs (DBPRS<25%).
CYP2D6 genotyping revealed intermediate metabolizer phenotypes for BD patients and an extensive metabolizer phenotype for the
patient without BD. In BD patients, the ratio of drugs maintained/discontinued for TFs or ADRs was 1.75 for non-CYP2D6 versus
0.33 for CYP2D6 interacting drugs, while the proportion of ADR:TF was 0:4 versus 6:3.
Lessons: Our findings may suggest that CYP2D6 clinically relevant genotypes may be involved in the unwanted outcomes
observed in RD patients with BD.
Abbreviations: ADRs = adverse drug reactions, BD = bipolar disorder, BPRS = Brief Psychiatric Rating Scale, CAN =
Camberwell Assessment of Need, CYP = cytochrome P450, DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, IV
Edition, Text Revised, RD = revolving door, TFs = therapeutic failures.
Keywords: adverse drug reaction, bipolar disorders, CYP2D6 polymorphisms, revolving door, therapeutic failure1. Introduction
Psychiatric illnesses, mainly bipolar disorder (BD), are chronic
and recurrent pathological conditions characterized by repeated
and severe changes in mood, leading to significant mental andEditor: N/A.
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social impairments with an increased risk for suicide, and thus
among the most important causes of death and disability
worldwide.[1] Psychiatric diseases affected 3% to 5% of the
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about $15B in the US and in Western countries.[3,4]
Evidenced-based treatment guidelines included a wide range of
medications for the clinical management of these patients, such as
mood stabilizers, first- and second-generation antipsychotics,
antidepressants, and anxiolytics, also in multidrug combina-
tions.[5,6] Despite the availability of this wide range of different
drug classes, however, psychiatrists still met great difficult in
treating psychiatric illnesses, since treatment response is often
inadequate, and the rate of remission is poor, particularly among
BD in the depressive phase.[7] Consequently, about 30% to 50%
of psychiatric patients showed therapeutic failures (TFs),
regardless of the initial choice of psychiatric medication.[8]
Finally, many drugs are poorly tolerated, and adverse drug
reactions (ADRs), like metabolic disturbances and extrapyrami-
dal symptoms, are common.[9–11]
Previous studies have correlated the length of psychiatric
hospitalization with cytochrome P450 (CYP)2D6 (CYP2D6)
functional status.[12,13] However, the recurring nature of the
psychopathological course of psychiatric illnesses, together with
the unwanted outcomes observed in these patients, are probable
the major responsible of the revolving door (RD) condition, a
periodical hospital readmission without any substantial improve-
ments in psychiatric symptoms,[14] further increasing costs for
their clinical management.
The identification of genetic factors underlying drug response is
among the most promising areas of research in psychiatric
medicine.[15–19] Currently, more than 20 psychotropic drugs have
been relabeled by the US Federal Drug Administration adding
information on polymorphic drug metabolism and therapeutic
recommendations.[15] In particular, CYP2D6 genetic variability
has been recently suggested to have a main role in the response to
treatment of psychiatric disorders[20–23] and in determining TFs
and ADRs to psychotropic drugs.[24–27] Several professional
societies have started to develop proper clinical guidelines to
maximize the therapeutic effects when minimizing the toxicity in
pharmacotherapy including the Clinical Pharmacogenetics Imple-
mentation Consortium[28] and the Dutch Pharmacogenetics
Working Group.[29] The objective of the present study was to
evaluate the contribution of CYP2D6 genetics to the unwanted
outcomes observed in a controlled series of 5 consecutive RD
patients with BD attending a psychiatric setting.
2. Methods
2.1. Study design and guidelines
This was a cross-sectional study of a controlled case series,
fulfilling the CARE guidelines,[30] Declaration of Helsinki
(available at URL http://www.wma.net/en), the guidelines for
Good Clinical Practice,[31] the National Institute for Health and
Care Excellence,[32] and the Canadian Network for Mood and
Anxiety Treatments guidelines.[5] Study design is summarized in
Table 1. The research project of the present study has been
approved from the Ethics Committees on human experimenta-
tion of the IRCCS “Casa Sollievo della Sofferenza,” San
Giovanni Rotondo, Foggia, Italy and the University of Foggia,
Foggia, Italy (Protocol number: 115/CE/2015, October 10,
2015). All the investigated patients gave their informed consent to
the publication of the cases in anonymous form.
2.2. Revolving door condition
TheRD conditionwas defined for those patients having aminimum
of 4 admissions, and no admission or discharge period lasting for2
more than1/4 of the observationperiod or at least 4 admissions over
thefirst 1/4of the observation period.[13] The time lapse inwhich the
RDconditionwasdefined is summarized inTable 1.Toavoidbias in
RD evaluation, that is, any clinical or social needs that aggravate the
disease or to explain disease exacerbation, possibly miming/
exacerbating the RD condition, the Camberwell Assessment of
Need (CAN) rating scale[33] was administered to each patient. A
CAN score<10 is the threshold for a patient to be considered as
having no significant clinical/social needs.2.3. Patient’s recruitment and inclusion/exclusion criteria
The study included all the RD patients that consecutively
admitted from January 1 to June 30, 2015 to the Psychiatric Unit
of the University of Foggia (Foggia, Italy). Written informed
consent for research was obtained from each patient’s relatives
before the enrollment. Inclusion criteria were: Caucasians race,
with Italian ancestry living in Italy for at least 2 generations, a
diagnosis of psychiatric illnesses according to the Diagnostic and
Statistical Manual of Mental Disorders, IV Edition, Text Revised
(DSM-IV-TR),[34] a RD condition identified in the past 3 years
(2013–2015), and a CAN score<10. Patients were excluded if
they have physical complications, history of seizure disorder,
dementia, and diabetes mellitus or abused psychoactive in the last
2 years. Subjects older than 70 years, or with intelligence
quotient<70, and women who were pregnant or breastfeeding,
were also excluded from the study.2.4. Therapeutic failures (TFs) and adverse drug reactions
(ADRs) assessment criteria
Psychiatric symptoms evaluation was conducted using the 24-
item Italian version of the Brief Psychiatric Rating Scale
Expanded Version 4.0 (BPRS).[35] According to Leucht
et al,[36] the response to treatment was defined by a change in
BPRS score ≥25% as evaluated at the beginning of (T0) and at 1
week (T1) of stable treatment (100% of medications adherence)
according to the following formula: DBPRS= (BPRSt1–BPRSt0)/
BPRSt0100. A DBPRS score <25% suggested a TF. Drug-
induced extrapyramidal symptoms were evaluated by means of
the Simpson Angus Scale (SAS).[37] An SAS score>0.3 and/or an
early drug-induced metabolic impairment with weight gain
according to percent change in body mass index (BMI)[38] were
considered as ADRs. An SAS score0.3 is considered within the
normal range. Both TFs and ADRs were evaluated by at least two
6-years experienced treating psychiatrists in blinded fashion.2.5. CYP2D6 genotype analysis
Genomic DNA was purified from frozen blood samples following
the salting-out method.[39] As previously reported,[40] the analysis
of the 16 clinical relevant polymorphisms CYP2D6∗2,
CYP2D6∗2A, CYP2D6∗3, CYP2D6∗4, CYP2D6∗5,
CYP2D6∗6,CYP2D6∗7,CYP2D6∗8,CYP2D6∗9,CYP2D6∗10,
CYP2D6∗12, CYP2D6∗14, CYP2D6∗17, CYP2D6∗29,
CYP2D6∗41, CYP2D6∗XN in the CYP2D6 gene was made in
blinded fashion by means of the INFINITI Analyzer (AutoGe-
nomics, Inc., Carlsbad, CA) using the INFINITI CYP4502D6-I
Assay according to manufacturer instructions. All the CYP2D6
genotypes were interpreted according to the Home Page of The
Human Cytochrome P450 (CYP) Allele Nomenclature Commit-
tee.[41] Indications about the metabolizer phenotypes resulting
from CYP2D6 genetics were reported as already described.[42,43]
Table 1
Time lapse in which the revolving door (RD) condition was defined in our case series of patients with psychiatric illnesses.









































Transfer from intensive care unit after attempted suicide.
† Voluntary discharge after 2 weeks.
‡ Transfer from Emergency Surgery Care Unit after attempted suicide.
x Voluntary discharge after 1 week.
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In the 6 months of recruitment, 5 consecutive psychiatric RD
patients (4 females and 1 male, mean age 44.40±7.23 years,
range from 37 to 54 years) were enrolled in the study. Three of
these patients received a diagnosis of type-II BD, whereas 1
patient received a diagnosis of type-I BD, and 1 patient a
diagnosis of bipolar-type schizoaffective disorder. Two patients
smoke n≥20 cigarettes/daily. In each patient, no neurological or
cognitive deficits were observed, with a computed tomography
(CT) scan image within normal limits. For each patient, a detailed
clinical history is reported in Supporting Document 1, and
summarized in Table 1, http://links.lww.com/MD/.
Patient 1 was a 44 years old female. Since 1995, the patient
received a diagnosis of chronic type-I BD.With a previous history
of attempted suicides, the patient was frequently admitted to the
Psychiatric Unit of the University of Foggia for recurrent mixed
mood states and obsessive–compulsive symptoms, frequently
associated with sexual and aggressive urges. Overall, a total of 8
drugs were administered to this patient. Across 4 hospital
readmissions 7 of these drugs were discontinued because to ADR3
or TF (Table 2, Fig. 1A). At the analysis of the CYP2D6 genotype,
the patient resultedCYP2D6∗2A/CYP2D6∗5. In detail, the allele
CYP2D6∗2A is associated to a minimal increased enzymatic
activity because of an higher promoter activity in vivo associated
with the A allele of the polymorphism G2,988→A (rs28371725),
always in linkage disequilibrium with the G allele of
rs1080985,[44] the single nucleotide polymorphisms (SNP)
labeling CYP2D6∗2A. On the other hand, the allele CYP2D6∗5,
consisting in a gene deletion, is representative of a missing
enzymatic activity (The Human Cytochrome P450 (CYP) Allele
Nomenclature Database). Thus, genotype CYP2D6∗2A/
CYP2D6∗5 was indicative of a reduced enzymatic activity that
can be assigned to the intermediate metabolizers (IMs).
Patient 2 was a 37 years old male. Since 2005, the patient
received a diagnosis of chronic bipolar-type schizoaffective
disorder, and was repeatedly admitted to the Psychiatric Unit of
the University of Foggia for psychotic exacerbation. The patient
presented auditory disturbances in the form of mandatory
hallucinations, ideas of reference and not-bizarre ideas with
suspiciousness, accompanied with a significant drop in social and
Table 2




























































Patient 1 ADR† TF OK TF ADR‡ TFx ADR TF
(BD-I) (D) (D) (M) (D) (D) (D) (D) (D)
Patient 2 OK OK TF TF TF TF
(non-BD) (M) (M) (D) (D) (D) (D)
Patient 3 ADR OK TF TF OK TF
(BD-II) (D) (M) (D) (D) (M) (D)
Patient 4 OK ADR OK ADR OK OK ADR TF OK
(BD-II) (M) (D) (M) (D) (M) (M) (D) (D) (M)
Patient 5 ADR ADR TF TF OK OK ADR OK TF ADR
(BD-II) (D) (D) (D) (D) (M) (M) (D) (M) (D) (D)
ADR/TF ADR ADR TF TF TF ADR/TF TF ADR/TF TF ADR TF TF ADR
Disc/maint M D D M D M D M D D M D M M D M M D M D D M D/M D
ADR= adverse drug reaction, BD=bipolar disorder, D=discontinued, M=maintained, OK=no ADR no TF, TF= therapeutic failure.
∗
CYP2D6 metabolism.
† Reintroduced to one-half dosage with no ADR.
‡ Introduced twice, and discontinued twice for ADR.
x The introduction of paliperidone pamoate resulted in an ADR.
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and drug ingestion and injection. Overall, a total of 6 drugs were
administered to this patient. Across 4 hospital readmissions 4 of
these drugs were discontinued because to TF (Table 2, Fig. 1B).
No ADR were observed in this patient. At the analysis of the
CYP2D6 genotype, the patient resulted CYP2D6∗1/
CYP2D6∗2A. In detail, in this patient the allele CYP2D6∗2A
(described for patient 1) is combined with CYP2D6∗1, the wild-
type allele (The Human Cytochrome P450 (CYP) Allele
Nomenclature Database). Thus, genotype CYP2D6∗1/
CYP2D6∗2A is indicative of a normal enzymatic activity that
can be assigned to the extensive metabolizers (EMs).
Patient 3 was a 49 years old female. Since 1996, the patient was
diagnosed as obsessive–compulsive disorders and, from 2013, as
type-II BD with psychotic behavior and recurrent depressive
episodes. At the first admission to the Psychiatric Unit of the
University of Foggia, the patient presented symptoms of sad
mood, social withdrawal, reduced speech output, forgetfulness,
motor movement and vocal sounds-like tics. The patient also
expressed death wishes and refuted to carry out even basic
activities of daily living. Overall a total of 6 drugs were
administered to this patient. Across 4 hospital readmissions 4 of
these drugs were discontinued because to ADRs or TFs overall TF
(Table 2, Fig. 1C). At the analysis of the CYP2D6 genotype, the
patient resulted CYP2D6∗2A/CYP2D6∗4. In detail, allele
CYP2D6∗2A (described for patient 1) was combined with allele
CYP2D6∗4, identified by a splicing defect associated to a not-
functional protein, responsible of a missing enzymatic activity
(The Human Cytochrome P450 (CYP) Allele Nomenclature
Database). Thus, genotype CYP2D6∗2A/CYP2D6∗4 was indic-
ative of a reduced enzymatic activity that can be assigned to the
IMs.
Patient 4 was a 54 years old female. Since 1984, she was
diagnosed as enduring type-II BD. Monthly admitted to the
Psychiatric Unit of the University of Foggia, the patient presented
perceptual disturbances in the form of content calling the
patient’s name, psychotic behavior with recurrent depressive
episodes frequently expressing death wishes with several previous
suicide attempts. A successive attempted suicide episode caused a
minor head injury. Overall a total of 9 drugs were administered to
this patient. Across 4 hospital readmissions, 4 of these drugs were
discontinued because to ADR or TF (Table 2, Fig. 1D). At the4
analysis of the CYP2D6 genotype, the patient resulted
CYP2D6∗4/CYP2D6∗17. In detail, the allele CYP2D6∗4
(described for patient 3) in this patient was combined with allele
CYP2D6∗17. This allele is identified by the amino acid changes
T107I (rs28371706) and R296C (rs16947), causing a reduced
CYP2D6 EA. Thus, genotype CYP2D6∗4/CYP2D6∗17 was
indicative of a reduced enzymatic activity (The Human
Cytochrome P450 (CYP) Allele Nomenclature Database) that
can be assigned to the IMs.
Patient 5 was a 38 years old female. Since 2005, she was
diagnosed as borderline personality disorders and, from 2013, as
type-II BD with recurrent depressive episodes. The patient was
frequently admitted to the Psychiatric Unit of the University of
Foggia because to increased anxiety, depression, irritability,
impulsivity, and suicidal ideation. Overall a total of 10 drugs
were administered to these patient. In particular, across 4 hospital
readmissions, 7 of these drugs were discontinued because to ADR
or TF (Table 2, Fig. 1E). At the analysis of the CYP2D6 genotype,
the patient resulted CYP2D6∗1/CYP2D6∗4. In detail, the allele
CYP2D6∗1 (already described for patient 2) and the allele
CYP2D6∗4 (already described for patients 3 and 4) were
combined in this genotype to give a reduced enzymatic activity
that can be assigned to the IMs.
At follow-up (Fig. 1), TFs were observed in the 3 patients
diagnosed as type-II BD (DBPRS%=11.50%, 11.11%, and
21.74% respectively for patients 3, 4, and 5), a probable response
was observed in patient 1, diagnosed as type-I BD (DBPRS%=
25.40%), and a response to treatment was observed in patient
without BD (DBPRS%=32.10%). In the BD patients, resulting
IMs, a comparison of non-CYP2D6 versus CYP2D6 interacting
drugs is summarized in Fig. 2. Overall, about one-half of the
administered drugs interact with CYP2D6 (45.45% vs 54.55%).
The ratio of drugs maintained versus discontinued resulted 1.75
versus 0.33. Among discontinued drugs, the ratio TF/ADRwas 0/
4 versus 6/3 (P= .070).
4. Discussion
In the present case-series study, we investigated the genetics of
CYP2D6 in RD patients with psychiatric illnesses, mainly BD.
The analysis of CYP2D6 clinical relevant polymorphisms
revealed that 4 patients, each affected by a diagnosis of BD,
Figure 1. (A–E) Unwanted outcomes to treatment of revolving door (RD) patients with psychiatric illnesses according to interaction of drugs with the cytochrome
P450 (CYP)2D6 (CYP2D6) enzyme. BPRS=Brief Psychiatric Rating Scale Expanded Version 4.0.
Seripa et al. Medicine (2018) 97:37 www.md-journal.comresulted IMs. Although the limited number of patients, we can
confirm that CYP2D6∗4 was the most common variant of
nonfunctional allele (3/5 of our patients), leading to the poor
metabolizer (PM) phenotype in Caucasians.[45] In the present
study, patients heterozygous for the CYP2D6∗4 allele have
slower rates of metabolism than EMs and are then classified as
IMs, although translation from this genotype to phenotype is
rather complex.[46] The only patient without BD diagnosis
resulted EM, and he was also the only one responding to drug
treatment and not showing ADR. The observed TFs in this latter
patient (4 drugs discontinued, 2 of which interacting with
CYP2D6) did not depend from the CYP2D6 genotypes, as well as
the good response to treatment at the end of the study.
On the other hand, we observed some differences between non-
CYP2D6 and CYP2D6 interacting drugs in the 4 BD patients,5
whom observed genotypes resulted in IM phenotypes. First of all,
the ratio of drugs maintained/discontinued was about 5-fold in
the first group; secondly, drugs discontinued for ADRwere 6-fold
in the second groups, since no drugs discontinued for ADR were
observed among not-CYP2D6 interacting drugs. Notably, only 1
patient with a diagnosis of type I BD at the end of the time lapse
defining the RD condition, showed a trend toward a response to
treatment.
At present, pharmacogenetic studies analyzing CYP2D6
activity are among the main aims in the field of psychiatry.
The majority of pharmacogenetic warnings in drug labeling for
psychiatric medications were related to variations at theCYP2D6
gene, the most polymorphic gene of the CYP superfamily.[41] To
date, pharmacogenetic studies have shown a significant correla-
tion between genotype and adverse effects associated with
[15,32]
Figure 2. Response to treatment of patients with psychiatric illnesses according to consecutive evaluations in the time lapse defining the revolving door (RD)
condition. ADR=adverse drug reaction, CYP2D6=cytochrome P450 (CYP)2D6, TF= therapeutic failure.
Seripa et al. Medicine (2018) 97:37 Medicineantipsychotics, justifying once again the importance of assessing
SNPs in patients treated with antipsychotics.[47] Despite these
evidences, the utility of CYP2D6 genotyping in predicting TFs
and ADRs in antipsychotic treatments was relatively unexplored.
In fact, notwithstanding the FDA approval of CYP450 testing for
27 alleles in CYP2D6.[48] the introduction of CYP2D6 genotyp-
ing in clinical practice is still difficult. Furthermore, previous
studies evaluated that cytochrome P450 PM polymorphisms of
CYP2D6 and CYP2C19 are relevant for the outcome (measured
by length of hospitalization) during treatment with psychotropic
medications in psychiatric inpatients.[12] In particular, few data
supported the possible involvement of CYP2D6-defective drug
metabolism in the RD condition of psychiatric patients.[49]
According to previous findings, about 50% of drugs we used in
the treatments of the patients cases series study, showed
interactions with CYP2D6.
Some major limitations to the present study must be
acknowledged. First of all, we cannot exclude a major role of
the other major CYPs in determining the outcomes observed in
our findings. In fact, evidence-based treatment guidelines
reported a wide range of medications for BD treatment, involving
a number of CYPs. Thus, it is clear that a further improvement in
understanding TFs and ADRs, and thus their contribution to the
RD condition, may result from the knowledge of the other main
CYP2C9, 2C19, and 3A4 variants, thus also explaining the TF/
ADR to drugs that shows alternative CYP2D6-metabolism.
Nevertheless, the main role of CYP2D6, the most polymorphic
CYP across this enzymatic system, in the metabolism of
psychotropic drugs has been well documented, thus making
CYP2D6 the first choice to investigate the genetic components
determining the response in psychiatric patients, and the use of
this genetic information a rational strategy for personalized6
medicine. Otherwise, the exclusion of CYP2D6 as the main
responsible of the observed outcomes can be useful to address the
analysis towards the other CYP-encoding genes. Furthermore,
the limited number of patients that were investigated was another
major limitation. It is clear that no statistical inference can be
made on 5 patients. But it is also clear that studies ad personam or
in a very limited number of patients are needed to promote
tailored medicine. Such studies did not need of statistical
associations, but of consideration on the single patients, that
must be treated individually on the basis of their genetic patterns.
These studies may be also useful to reduce prevent TFs and/or
ADRs, resulting in a reduction of therapeutic attempts, with a
reduction in the number of the administered drugs, and of
hospital readmission, overall improving the clinical management
of these patients. Accordingly, a reduction in the overall expenses
of the national health system is also expected. The usefulness of
case series in psychiatric translational research has been recently
reported.[50] Thus, more studies onwider case series are needed to
definitively assess the contribution of CYP2D6 genetics and
metabolism to TFs and ADRs observed in RD patients attending
psychiatric settings.Author contributions
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